Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8757492 | 0.94 | HPGD (0.50) | HPGDSMN1; SMN2USP2TP53ALOX12 | |
| SCHEMBL29133621 | 0.81 | HPGD (0.49) | HPGDSMN1; SMN2USP2TP53ALOX12 | |
| SCHEMBL26009956 | 0.81 | HPGD (0.45) | HPGDSMN1; SMN2USP2TP53ALOX12 | |
| SCHEMBL14748210 | 0.79 | HPGD (0.58) | HPGDSMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL15866467 | 0.79 | HPGD (0.58) | HPGDSMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL8877070 | 0.79 | HPGD (0.45) | HPGDSMN1; SMN2USP2TP53ALOX12 | |
| SCHEMBL17997798 | 0.79 | HPGD (0.45) | HPGDSMN1; SMN2USP2TP53ALOX12 | |
| SCHEMBL23668701 | 0.78 | HPGD (0.47) | HPGDSMN1; SMN2USP2TP53ALOX12 | |
| SCHEMBL23668692 | 0.78 | HPGD (0.47) | HPGDSMN1; SMN2USP2TP53ALOX12 | |
| SCHEMBL23668706 | 0.78 | HPGD (0.47) | HPGDSMN1; SMN2USP2TP53ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | HPGD 2948/4885SMN1; SMN2 4237/4885USP2 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.